Will T-cell therapy for cancer ever be a standard of care?
Cellular therapies for cancer are showing increasing efficacy but their introduction as a 'standard of care' for these disorders is hampered by technical, regulatory and financial concerns. This review identifies some of the major problems and suggests potential solutions.